Overview

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Status:
Recruiting

Trial end date:
2021-09-28

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the tolerability, safety, and pharmacokinetics of HYQVIA with ramp-up and no ramp-up dosing in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Baxalta now part of Shire

Collaborator:

Baxalta Innovations GmbH, now part of Shire

Treatments:

Immunoglobulins